Guardant Health Stock Price, News & Analysis

Guardant Health reported Q2 2022 revenue of $109.1 million, marking a 19% increase from last year. Clinical and biopharma testing volumes surged by 40% and 65%, respectively. The company achieved Medicare coverage for Guardant Reveal™, enhancing access for colorectal cancer patients. Despite revenue growth, operating expenses rose 27% to $202.7 million, and net loss increased to $229.4 million. The firm expects 2022 revenue to reach $460 million to $470 million, indicating a 23% to 26% growth.

Guardant Health, Inc. (NASDAQ: GH) announced that its Guardant Reveal™ blood test for molecular residual disease (MRD) is now covered for fee-for-service Medicare patients in the US with stage II or III colorectal cancer (CRC). This coverage enables oncologists to detect circulating tumor DNA (ctDNA) in patients post-surgery, enhancing treatment decisions. The test marks a significant milestone as the first blood-only liquid biopsy for MRD testing in CRC. This decision complements existing Medicare coverage for other Guardant Health tests, boosting the company's position in precision oncology.

Guardant Health (NASDAQ: GH) will report its second quarter 2022 financial results after market close on August 4, 2022. A conference call is scheduled for 1:30 PM PT (4:30 PM ET) to discuss the results. The live audio webcast will be accessible via the company’s website and will be archived for future viewing.

Guardant Health is a leader in precision oncology, offering a range of tests for various cancer stages, including Guardant360 and Shield. These innovations aim to enhance cancer screening and treatment outcomes globally.

Guardant Health (Nasdaq: GH) has appointed Steve E. Krognes to its board of directors, enhancing its leadership amidst evolving market dynamics. Krognes brings over 20 years of experience in the biotech sector, having served in key roles including CFO at Denali Therapeutics and Genentech. His expertise in financial management and corporate strategy is expected to guide Guardant Health in its growth trajectory, particularly as it continues to advance its proprietary oncology tests and analytics aimed at improving cancer care.

Guardant Health (Nasdaq: GH) and Adicon Holdings Limited have formed a strategic partnership to provide comprehensive genomic profiling tests to biopharmaceutical companies in China. This collaboration will enable access to Guardant's liquid biopsy technologies, including Guardant360® and GuardantOMNI™, enhancing patient screening for clinical trials. Particularly, the partnership addresses the high cancer incidence in China, with the need for innovative therapies. This partnership reflects Guardant's commitment to advancing cancer care through cutting-edge diagnostics.

Guardant Health (NASDAQ:GH) has acquired the remaining shares of Guardant Health AMEA, Inc. from SoftBank for approximately $177.8 million, achieving full operational control in the Asia, Middle East, and Africa regions. This strategic move allows Guardant Health to enhance its response to the significant cancer burden in these areas, where over half of the world's new cancer cases arise. The company aims to expedite the adoption of its blood tests, notably the Guardant360 CDx, following regulatory approval in Japan.

Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, will participate in two upcoming investor conferences. The first is the William Blair 42nd Annual Growth Stock Conference in Chicago on June 7 at 11:20 a.m. CT. The second is the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes on June 14 at 9:20 a.m. PT. Live and archived webcasts will be available on the company's website. Guardant Health focuses on advanced cancer tests to improve patient outcomes and reduce healthcare costs.

Guardant Health (Nasdaq: GH) has launched the first blood-based cancer testing services in Europe at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. This partnership, established in January 2021, aims to enhance access to Guardant’s liquid biopsy technology. The service provides comprehensive genomic profiling to identify actionable biomarkers quickly from a blood draw, aiding in treatment decisions for late-stage cancer patients. With over 282,000 new cancer cases reported in Spain in 2020, this innovation seeks to improve patient outcomes through precision oncology.

Guardant Health will present new data at the 2022 ASCO Annual Meeting, taking place from June 3-7 in Chicago. Highlights include an oral presentation utilizing real-world data from GuardantINFORM to identify resistance to early treatment in advanced breast cancer and an updated progression-free survival analysis of fulvestrant plus capivasertib versus fulvestrant plus placebo in metastatic breast cancer. The company aims to demonstrate the utility of blood tests in optimizing patient care and improving outcomes.